Free Trial

Teva Pharmaceutical Industries (TEVA) Financials

Teva Pharmaceutical Industries logo
$43.57 -0.93 (-2.09%)
As of 12:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Teva Pharmaceutical Industries

Annual Income Statements for Teva Pharmaceutical Industries

This table shows Teva Pharmaceutical Industries' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
1,573 68 -16,525 -2,399 -999 -3,990 417 -2,446 -559 -1,639 1,410
Consolidated Net Income / (Loss)
1,597 311 -16,449 -2,472 -1,000 -4,099 456 -2,499 -615 -1,959 1,418
Net Income / (Loss) Continuing Operations
1,597 311 -16,449 -2,472 -1,000 -4,100 456 -2,499 -615 -1,959 1,418
Total Pre-Tax Income
2,352 824 -18,379 -2,596 -1,265 -4,406 658 -3,163 -624 -1,284 1,223
Total Operating Income
3,352 2,154 -17,484 -1,637 -443 -3,572 1,716 -2,197 433 -303 2,157
Total Gross Profit
11,356 11,653 10,615 8,296 7,537 7,726 7,594 6,973 7,645 8,064 8,938
Total Revenue
19,652 21,903 21,853 18,271 16,887 16,659 15,878 14,925 15,846 16,544 17,258
Operating Revenue
19,652 21,903 21,853 18,271 16,887 16,659 15,878 14,925 15,846 16,544 17,258
Total Cost of Revenue
8,296 10,250 11,237 9,975 9,351 8,933 8,284 7,952 8,200 8,481 8,320
Operating Cost of Revenue
8,296 10,250 11,237 9,975 9,351 8,933 8,284 7,952 8,200 8,481 8,320
Total Operating Expenses
8,004 9,499 28,099 9,933 7,980 11,297 5,879 9,170 7,213 8,366 6,780
Selling, General & Admin Expense
1,360 1,390 1,451 1,298 1,192 1,173 1,099 1,180 1,162 1,161 1,287
Marketing Expense
3,478 3,583 3,395 2,916 2,614 2,498 2,429 2,265 2,336 2,541 2,686
Research & Development Expense
1,525 2,077 1,778 1,213 1,010 997 967 838 953 998 1,013
Other Operating Expenses / (Income)
-166 -769 -1,199 -291 -76 -40 -98 -107 -49 -14 18
Impairment Charge
1,176 2,319 20,338 5,018 1,639 6,130 424 2,400 1,050 1,531 259
Restructuring Charge
- - 1,836 987 423 479 341 512 718 1,388 1,050
Other Special Charges / (Income)
631 899 500 -1,208 1,178 60 717 2,082 1,043 761 467
Total Other Income / (Expense), net
-1,000 -1,330 -895 -959 -822 -834 -1,058 -966 -1,057 -981 -934
Other Income / (Expense), net
-1,000 -1,330 -895 -959 -822 -834 -1,058 -966 -1,057 -981 -934
Income Tax Expense
634 521 -1,933 -195 -278 -168 211 -643 -7.00 676 -180
Other Gains / (Losses), net
-121 8.00 -3.00 -71 -13 138 9.00 21 2.00 1.00 15
Net Income / (Loss) Attributable to Noncontrolling Interest
9.00 -18 -184 -322 -2.00 -109 39 -53 -56 -320 7.00
Basic Earnings per Share
$1.84 $0.07 ($16.26) ($2.35) ($0.91) ($3.64) $0.38 ($2.20) ($0.50) ($1.45) $1.23
Weighted Average Basic Shares Outstanding
855M 955M 1.02B 1.02B 1.09B 1.10B 1.10B 1.11B 1.12B 1.13B 1.15B
Diluted Earnings per Share
$1.82 $0.07 ($16.26) ($2.35) ($0.91) ($3.64) $0.38 ($2.20) ($0.50) ($1.45) $1.21
Weighted Average Diluted Shares Outstanding
1.02B 961M 1.02B 1.02B 1.09B 1.10B 1.11B 1.11B 1.12B 1.13B 1.16B
Weighted Average Basic & Diluted Shares Outstanding
1.02B 1.12B 1.02B 1.02B 1.09B 1.10B 1.10B 1.11B 1.12B 1.13B 1.15B

Quarterly Income Statements for Teva Pharmaceutical Industries

This table shows Teva Pharmaceutical Industries' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-139 -846 -437 -217 214 282 433 481 369 -576 233
Consolidated Net Income / (Loss)
-419 -874 -390 -276 220 283 434 481 369 -575 234
Net Income / (Loss) Continuing Operations
-419 -874 -390 -276 220 280 434 482 369 -576 234
Total Pre-Tax Income
-467 -246 -324 -247 294 203 646 80 437 -455 300
Total Operating Income
-218 -5.00 -51 -29 519 455 882 301 652 -231 714
Total Gross Profit
1,771 2,024 2,148 2,121 1,877 2,102 2,304 2,655 1,972 2,153 2,440
Total Revenue
3,819 4,164 4,332 4,229 3,891 4,176 4,480 4,711 3,982 4,142 4,395
Operating Revenue
3,819 4,164 4,332 4,229 3,891 4,176 4,480 4,711 3,982 4,142 4,395
Total Cost of Revenue
2,048 2,140 2,183 2,110 2,014 2,074 2,176 2,056 2,011 1,989 1,955
Operating Cost of Revenue
2,048 2,140 2,183 2,110 2,014 2,074 2,176 2,056 2,011 1,989 1,955
Total Operating Expenses
1,988 2,030 2,198 2,150 1,356 1,647 1,422 2,355 1,319 2,384 1,726
Selling, General & Admin Expense
278 283 298 302 297 305 317 368 304 317 298
Marketing Expense
608 656 626 651 622 654 656 754 696 717 709
Research & Development Expense
242 269 240 247 247 244 256 266 222 970 297
Other Operating Expenses / (Income)
1.00 -2.00 -21 8.00 5.00 4.00 7.00 2.00 -9.00 -19 -68
Impairment Charge
80 461 628 362 121 42 64 32 8.00 22 24
Restructuring Charge
673 280 -23 458 -22 232 62 778 26 147 264
Other Special Charges / (Income)
106 83 450 122 86 166 60 155 72 230 202
Total Other Income / (Expense), net
-250 -241 -272 -218 -225 -252 -237 -220 -216 -224 -414
Other Income / (Expense), net
-250 -241 -272 -218 -225 -252 -237 -220 -216 -224 -414
Income Tax Expense
-52 630 69 29 74 -78 214 -390 67 121 66
Other Gains / (Losses), net
-4.00 2.00 3.00 - 0.00 -1.00 2.00 12 -1.00 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest
-280 -29 47 -58 6.00 0.00 1.00 - 0.00 0.00 1.00
Basic Earnings per Share
($0.12) ($0.75) ($0.39) ($0.19) $0.19 $0.25 $0.38 $0.41 $0.32 ($0.49) $0.20
Weighted Average Basic Shares Outstanding
1.12B 1.13B 1.13B 1.13B 1.14B 1.15B 1.15B 1.15B 1.16B 1.17B 1.17B
Diluted Earnings per Share
($0.12) ($0.75) ($0.39) ($0.19) $0.18 $0.24 $0.37 $0.42 $0.31 ($0.49) $0.20
Weighted Average Diluted Shares Outstanding
1.12B 1.13B 1.13B 1.13B 1.16B 1.16B 1.16B 1.16B 1.18B 1.17B 1.18B
Weighted Average Basic & Diluted Shares Outstanding
1.13B 1.13B 1.13B 1.13B 1.15B 1.15B 1.15B 1.15B 1.16B 1.17B 1.17B

Annual Cash Flow Statements for Teva Pharmaceutical Industries

This table details how cash moves in and out of Teva Pharmaceutical Industries' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
4,720 -5,958 -25 4,607 1,073 202 1,850 636 393 74 256
Net Cash From Operating Activities
5,542 3,890 2,225 2,446 748 1,216 798 1,590 1,368 1,247 1,649
Net Cash From Continuing Operating Activities
5,542 3,890 2,225 6,092 1,644 1,216 2,499 1,590 1,368 1,247 1,649
Net Income / (Loss) Continuing Operations
1,597 311 -16,449 -2,472 -1,000 -4,099 456 -2,499 -615 -1,959 1,418
Consolidated Net Income / (Loss)
1,597 311 -16,449 -2,472 -1,000 -4,099 456 -2,499 -615 -1,959 1,418
Depreciation Expense
1,308 1,524 2,112 1,842 1,722 1,557 1,330 1,308 1,153 1,059 1,002
Non-Cash Adjustments To Reconcile Net Income
1,287 2,170 20,525 3,960 2,273 6,542 1,391 2,581 1,158 2,656 1,185
Changes in Operating Assets and Liabilities, net
1,350 -115 -3,963 -884 -1,351 -2,784 -678 200 -328 -509 -1,956
Net Cash From Investing Activities
-5,565 -34,405 3,446 1,866 1,355 863 1,523 656 968 792 737
Net Cash From Continuing Investing Activities
-5,565 -34,405 3,446 1,866 1,355 863 1,523 656 968 792 737
Purchase of Property, Plant & Equipment
-772 -901 -874 -651 -525 -578 -562 -548 -526 -498 -501
Acquisitions
-3,309 -36,148 - - - 0.00 0.00 -7.00 0.00 -15 0.00
Purchase of Investments
-2,003 -481 -200 -119 -8.00 -55 -47 -1.00 -46 -71 -57
Divestitures
- - 43 - 343 67 311 68 68 43 34
Sale and/or Maturity of Investments
524 2,002 3,477 890 2.00 12 172 4.00 0.00 40 42
Other Investing Activities, net
-5.00 1,123 1,000 1,746 1,543 1,417 1,649 1,140 1,472 1,293 1,219
Net Cash From Financing Activities
4,805 25,217 -5,750 -3,351 -1,926 -1,885 -2,172 -1,487 -1,913 -1,791 -2,151
Net Cash From Continuing Financing Activities
4,805 25,217 -5,750 -3,351 -1,926 -1,885 -2,172 -1,487 -1,913 -1,791 -2,151
Repayment of Debt
-2,699 -1,168 -5,057 -7,763 -2,374 -2,435 -2,381 -1,487 -5,064 -1,649 -4,071
Payment of Dividends
-1,155 -1,558 -1,199 -22 -52 - - 0.00 0.00 -78 -340
Issuance of Debt
2,128 27,250 506 4,434 500 550 700 0.00 3,151 0.00 2,298
Other Financing Activities, net
388 35 - - 0.00 - -491 0.00 0.00 -64 -38
Other Net Changes in Cash
- -660 54 - - 8.00 - -123 -30 -174 21
Cash Interest Paid
243 290 795 815 840 846 913 948 1,078 1,004 950

Quarterly Cash Flow Statements for Teva Pharmaceutical Industries

This table details how cash moves in and out of Teva Pharmaceutical Industries' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-236 -733 1,061 -18 -1,603 464 42 1,353 185 714 -370
Net Cash From Operating Activities
-124 103 693 575 -105 227 369 1,158 -40 411 241
Net Cash From Continuing Operating Activities
-124 103 693 575 -105 227 369 1,158 -40 1,190 -539
Net Income / (Loss) Continuing Operations
-419 -875 -390 -275 220 283 434 481 369 -575 233
Consolidated Net Income / (Loss)
-419 -875 -390 -275 220 283 434 481 369 -575 233
Depreciation Expense
272 259 259 269 244 250 248 260 239 241 245
Non-Cash Adjustments To Reconcile Net Income
707 561 557 831 113 138 112 824 45 851 495
Changes in Operating Assets and Liabilities, net
-684 158 267 -250 -682 -444 -425 -407 -693 673 -1,512
Net Cash From Investing Activities
144 178 268 202 201 236 135 165 229 -492 211
Net Cash From Continuing Investing Activities
144 178 268 202 201 236 135 165 229 -491 210
Purchase of Property, Plant & Equipment
-124 -97 -148 -129 -127 -96 -136 -142 -168 -105 -120
Divestitures
0.00 1.00 38 19 17 9.00 8.00 - 42 4.00 47
Other Investing Activities, net
295 317 339 342 322 339 276 282 355 -389 1,029
Net Cash From Financing Activities
-151 -966 - -674 -1,744 6.00 -453 40 13 -1.00 6.00
Net Cash From Continuing Financing Activities
-151 -966 - -674 -1,743 5.00 -453 40 13 -1.00 5.00
Repayment of Debt
-9.00 -966 - -674 -1,365 -2,300 1,852 -2,258 13 -1.00 5.00

Annual Balance Sheets for Teva Pharmaceutical Industries

This table presents Teva Pharmaceutical Industries' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
54,233 93,057 70,615 60,683 57,470 50,640 47,666 44,011 43,479 39,326 40,748
Total Current Assets
18,398 17,228 15,382 13,794 13,464 13,005 12,573 12,051 12,485 12,552 13,946
Cash & Equivalents
6,946 988 963 1,782 1,975 2,177 2,165 2,801 3,226 3,300 3,556
Accounts Receivable
5,350 7,523 7,128 5,822 5,676 4,581 4,529 3,696 3,408 3,059 3,709
Inventories, net
3,966 4,954 4,924 4,731 4,422 4,403 3,818 3,833 4,021 3,007 3,179
Prepaid Expenses
910 1,629 1,100 899 870 945 1,075 1,162 1,255 1,006 1,122
Other Current Assets
491 2,134 701 468 434 710 965 549 504 409 539
Other Current Nonoperating Assets
- - 566 92 87 189 19 10 70 1,771 1,842
Plant, Property, & Equipment, net
6,544 8,073 7,673 6,868 6,436 6,296 5,982 5,739 5,750 4,581 4,080
Total Noncurrent Assets
29,291 67,756 47,560 40,021 37,569 31,339 29,112 26,221 25,243 22,193 22,722
Goodwill
19,025 44,409 28,414 24,917 24,846 20,624 20,040 17,633 17,177 15,147 16,000
Intangible Assets
7,675 21,487 17,640 14,005 11,232 8,923 7,466 6,270 5,387 4,418 3,781
Noncurrent Deferred & Refundable Income Taxes
250 625 574 368 386 695 596 1,458 1,812 1,799 2,191
Other Noncurrent Operating Assets
2,341 1,235 932 731 1,105 1,097 1,010 860 867 829 750
Total Liabilities & Shareholders' Equity
54,233 93,057 70,615 60,683 57,470 50,640 47,666 44,011 43,479 39,326 40,748
Total Liabilities
24,306 58,064 51,870 44,889 42,407 39,579 36,422 35,413 35,353 33,606 32,834
Total Current Liabilities
13,005 18,488 17,921 14,322 13,674 13,164 11,027 11,469 12,247 12,796 13,456
Short-Term Debt
1,585 3,276 3,646 2,216 2,345 3,188 1,426 2,109 1,672 1,781 1,820
Accounts Payable
1,918 2,157 2,069 1,853 1,718 1,756 1,686 1,887 2,602 2,203 2,531
Accrued Expenses
1,681 3,405 3,014 1,868 1,869 1,780 2,208 2,151 2,771 2,792 2,687
Current Employee Benefit Liabilities
- - 549 870 693 685 563 566 611 624 739
Other Current Liabilities
7,821 9,534 8,605 7,515 7,048 5,757 5,144 4,755 4,579 4,698 5,325
Other Current Nonoperating Liabilities
0.00 116 38 - - - - - 13 698 354
Total Noncurrent Liabilities
11,301 39,576 33,949 30,567 28,733 26,414 25,395 23,944 23,106 20,809 19,379
Long-Term Debt
8,358 32,524 28,829 26,700 24,562 22,731 21,617 19,103 18,161 16,002 14,986
Noncurrent Deferred & Payable Income Tax Liabilities
1,748 5,413 3,277 2,140 1,096 964 784 548 606 483 296
Other Noncurrent Operating Liabilities
1,195 1,639 1,843 1,727 3,075 2,719 2,994 4,294 4,339 4,324 4,096
Commitments & Contingencies
0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
29,927 34,993 18,745 15,794 15,063 11,061 11,244 8,598 8,126 5,380 7,914
Total Preferred & Common Equity
29,769 33,337 17,359 14,707 13,972 10,026 10,278 7,804 7,506 5,373 7,910
Total Common Equity
26,478 29,717 13,728 14,707 13,972 10,027 10,278 7,804 7,505 5,373 7,910
Common Stock
17,809 23,463 23,533 27,266 27,368 27,500 27,618 27,745 27,864 27,822 28,191
Retained Earnings
14,851 13,607 -3,803 -5,958 -6,956 -10,946 -10,529 -12,975 -13,534 -15,173 -13,762
Treasury Stock
-4,227 -4,194 -4,149 -4,142 -4,128 -4,128 -4,128 -4,128 -4,128 -4,128 -4,128
Accumulated Other Comprehensive Income / (Loss)
-1,955 -3,159 -1,853 -2,459 -2,312 -2,399 -2,683 -2,838 -2,697 -3,148 -2,391
Noncontrolling Interest
158 1,656 1,386 1,087 1,091 1,035 966 794 620 7.00 4.00

Quarterly Balance Sheets for Teva Pharmaceutical Industries

This table presents Teva Pharmaceutical Industries' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
43,095 42,088 42,773 41,338 41,758 38,415 40,131 39,856 40,040 39,857 40,042
Total Current Assets
12,088 11,425 12,297 11,632 12,314 11,528 12,620 12,736 13,710 13,760 14,602
Cash & Equivalents
2,669 2,249 2,991 2,258 3,319 1,697 2,161 2,203 3,741 3,655 4,085
Accounts Receivable
3,539 3,385 3,456 3,766 3,462 3,384 3,564 3,810 3,393 3,493 3,837
Inventories, net
4,109 4,051 3,949 3,927 3,959 3,247 3,497 3,323 3,176 3,221 3,173
Prepaid Expenses
1,228 1,168 1,336 1,096 1,127 1,018 1,084 1,115 1,070 1,034 1,014
Other Current Assets
486 520 495 517 445 368 472 477 535 563 658
Other Current Nonoperating Assets
56 51 70 69 2.00 1,814 1,842 1,809 1,794 1,794 1,836
Plant, Property, & Equipment, net
5,712 5,622 5,618 5,573 5,672 4,631 4,810 4,820 3,998 3,928 3,747
Total Noncurrent Assets
25,295 25,041 24,857 24,133 23,773 22,255 22,700 22,301 22,333 22,168 21,692
Goodwill
17,118 16,885 17,007 16,488 16,124 15,477 15,949 15,945 15,822 15,839 15,742
Intangible Assets
5,738 5,525 5,056 4,853 4,756 4,189 4,142 3,936 3,609 3,447 3,303
Noncurrent Deferred & Refundable Income Taxes
1,578 1,748 1,960 2,000 2,070 1,762 1,781 1,634 2,190 2,162 2,057
Other Noncurrent Operating Assets
861 883 834 792 823 827 828 786 712 720 590
Total Liabilities & Shareholders' Equity
43,095 42,088 42,773 41,338 41,758 38,415 40,131 39,856 40,040 39,857 40,042
Total Liabilities
35,387 34,576 35,230 34,774 35,375 32,146 33,297 32,602 31,809 32,100 32,057
Total Current Liabilities
11,843 11,394 13,792 13,037 13,797 11,157 11,861 11,491 13,532 15,646 15,425
Short-Term Debt
1,980 1,479 3,060 2,094 2,580 421 464 24 2,612 4,500 4,038
Accounts Payable
2,508 2,280 2,439 2,366 2,371 2,290 2,498 2,355 2,596 2,721 2,551
Accrued Expenses
2,498 2,741 2,784 2,840 2,984 2,952 3,095 2,989 2,616 2,738 2,962
Current Employee Benefit Liabilities
451 530 492 492 619 474 481 561 555 488 588
Other Current Liabilities
4,406 4,362 4,755 4,891 5,026 4,660 4,990 5,237 4,818 4,886 4,991
Other Current Nonoperating Liabilities
- - 262 356 216 358 334 324 334 313 296
Total Noncurrent Liabilities
23,543 23,182 21,438 21,737 21,578 20,990 21,436 21,111 18,277 16,454 16,632
Long-Term Debt
18,698 18,495 16,584 16,547 16,400 16,230 16,763 16,766 14,015 12,092 12,680
Noncurrent Deferred & Payable Income Tax Liabilities
534 544 569 553 538 461 440 399 273 289 263
Other Noncurrent Operating Liabilities
4,311 4,142 4,285 4,637 4,639 4,299 4,234 3,947 3,989 4,073 3,688
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Total Equity & Noncontrolling Interests
7,708 7,512 7,543 6,563 6,383 6,269 6,834 7,254 8,232 7,757 7,984
Total Preferred & Common Equity
7,052 6,929 7,278 6,359 6,065 6,262 6,827 7,250 8,228 7,753 7,979
Total Common Equity
7,050 6,929 7,278 6,359 6,065 6,262 6,826 7,250 8,228 7,753 7,979
Common Stock
27,805 27,837 27,854 27,887 27,918 28,023 28,061 28,096 28,262 28,315 28,368
Retained Earnings
-13,950 -13,870 -13,673 -14,519 -14,956 -14,958 -14,676 -14,243 -13,394 -13,969 -13,736
Treasury Stock
-4,128 -4,128 -4,128 -4,128 -4,128 -4,128 -4,128 -4,128 -4,128 -4,128 -4,097
Accumulated Other Comprehensive Income / (Loss)
-2,677 -2,910 -2,775 -2,881 -2,769 -2,675 -2,431 -2,475 -2,512 -2,465 -2,556
Noncontrolling Interest
656 582 265 204 319 7.00 7.00 4.00 4.00 4.00 5.00

Annual Metrics And Ratios for Teva Pharmaceutical Industries

This table displays calculated financial ratios and metrics derived from Teva Pharmaceutical Industries' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-3.06% 11.45% -0.23% -16.39% -7.57% -1.35% -4.69% -6.00% 6.17% 4.40% 4.32%
EBITDA Growth
-28.88% -35.85% -792.80% 95.36% 160.61% -723.41% 169.78% -193.31% 128.52% -142.53% 1,088.89%
EBIT Growth
-35.35% -64.97% -2,330.46% 85.88% 51.27% -248.30% 114.93% -580.70% 80.27% -105.77% 195.25%
NOPAT Growth
-26.01% -67.65% -1,645.18% 90.64% 72.94% -706.32% 146.62% -231.93% 119.71% -169.98% 1,266.65%
Net Income Growth
-47.50% -80.53% -5,389.07% 84.97% 59.55% -309.90% 111.12% -648.03% 75.39% -218.54% 172.38%
EPS Growth
-48.88% -96.15% -23,328.57% 85.55% 61.28% -300.00% 110.44% -678.95% 77.27% -190.00% 183.45%
Operating Cash Flow Growth
8.09% -29.81% -42.80% 9.93% -69.42% 62.57% -34.38% 99.25% -13.96% -8.85% 32.24%
Free Cash Flow Firm Growth
-82.62% -3,792.71% 121.97% -27.74% -54.45% 6.75% 31.57% -3.04% -26.25% 102.73% -63.82%
Invested Capital Growth
4.67% 112.37% -28.88% -13.86% -6.84% -13.27% -7.25% -15.90% -8.62% -22.46% 2.85%
Revenue Q/Q Growth
0.00% 0.00% 0.00% -4.64% 3.00% -0.08% -2.19% -1.43% 3.76% -1.36% 2.87%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% 92.77% 115.62% 5.10% -16.26% -126.77% 146.57% -142.86% 16.74%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 79.09% 72.58% 3.80% -32.09% -47.80% 73.21% -141.81% 36.65%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 85.75% 88.20% 6.71% -26.71% -88.42% 133.93% -162.99% 84.71%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 77.44% 76.84% 2.06% -40.70% -91.49% 74.67% -61.10% 114.52%
EPS Q/Q Growth
0.00% 0.00% 0.00% 78.42% 76.61% 0.82% -42.42% -89.66% 76.19% -72.62% 101.67%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 0.00% -16.75% 29.64% -14.55% 18.57% 48.18% 18.24% -32.81% 54.69%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% -23.69% -23.56% 34.51% -5.38% 6.71% 63.31% -40.53%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% -8.21% -1.72% 1.00% -3.10% -5.42% -2.04% -14.06% -3.35%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
57.79% 53.20% 48.57% 45.41% 44.63% 46.38% 47.83% 46.72% 48.25% 48.74% 51.79%
EBITDA Margin
18.62% 10.72% -74.44% -4.13% 2.71% -17.10% 12.52% -12.43% 3.34% -1.36% 12.89%
Operating Margin
17.06% 9.83% -80.01% -8.96% -2.62% -21.44% 10.81% -14.72% 2.73% -1.83% 12.50%
EBIT Margin
11.97% 3.76% -84.10% -14.21% -7.49% -26.45% 4.14% -21.19% -3.94% -7.76% 7.09%
Profit (Net Income) Margin
8.13% 1.42% -75.27% -13.53% -5.92% -24.61% 2.87% -16.74% -3.88% -11.84% 8.22%
Tax Burden Percent
67.90% 37.74% 89.50% 95.22% 79.05% 93.03% 69.30% 79.01% 98.56% 152.57% 115.94%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
26.96% 63.23% 0.00% 0.00% 0.00% 0.00% 32.07% 0.00% 0.00% 0.00% -14.72%
Return on Invested Capital (ROIC)
7.61% 1.54% -20.46% -2.48% -0.75% -6.71% 3.49% -5.20% 1.17% -0.97% 12.75%
ROIC Less NNEP Spread (ROIC-NNEP)
-7.74% -1.00% -33.23% -7.05% -3.41% -13.32% 0.30% -10.10% -4.08% -12.63% 4.36%
Return on Net Nonoperating Assets (RNNOA)
-1.61% -0.58% -40.76% -11.84% -5.73% -24.67% 0.59% -19.98% -8.53% -27.33% 8.05%
Return on Equity (ROE)
5.99% 0.96% -61.22% -14.31% -6.48% -31.38% 4.09% -25.19% -7.35% -28.30% 20.80%
Cash Return on Invested Capital (CROIC)
3.05% -70.41% 13.29% 12.42% 6.33% 7.50% 11.02% 12.06% 10.18% 24.34% 9.94%
Operating Return on Assets (OROA)
4.67% 1.12% -22.46% -3.95% -2.14% -8.15% 1.34% -6.90% -1.43% -3.10% 3.05%
Return on Assets (ROA)
3.17% 0.42% -20.10% -3.77% -1.69% -7.58% 0.93% -5.45% -1.41% -4.73% 3.54%
Return on Common Equity (ROCE)
5.60% 0.83% -49.49% -11.78% -6.02% -28.83% 3.72% -22.95% -6.73% -26.32% 20.27%
Return on Equity Simple (ROE_SIMPLE)
5.36% 0.93% -94.76% -16.81% -7.16% -40.88% 4.44% -32.02% -8.19% -36.46% 0.00%
Net Operating Profit after Tax (NOPAT)
2,448 792 -12,239 -1,146 -310 -2,500 1,166 -1,538 303 -212 2,474
NOPAT Margin
12.46% 3.62% -56.01% -6.27% -1.84% -15.01% 7.34% -10.30% 1.91% -1.28% 14.34%
Net Nonoperating Expense Percent (NNEP)
15.34% 2.54% 12.78% 4.57% 2.66% 6.61% 3.20% 4.90% 5.25% 11.66% 8.39%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -5.16% 1.08% -0.92% 10.01%
Cost of Revenue to Revenue
42.21% 46.80% 51.42% 54.59% 55.37% 53.62% 52.17% 53.28% 51.75% 51.26% 48.21%
SG&A Expenses to Revenue
6.92% 6.35% 6.64% 7.10% 7.06% 7.04% 6.92% 7.91% 7.33% 7.02% 7.46%
R&D to Revenue
7.76% 9.48% 8.14% 6.64% 5.98% 5.98% 6.09% 5.61% 6.01% 6.03% 5.87%
Operating Expenses to Revenue
40.73% 43.37% 128.58% 54.36% 47.26% 67.81% 37.03% 61.44% 45.52% 50.57% 39.29%
Earnings before Interest and Taxes (EBIT)
2,352 824 -18,379 -2,596 -1,265 -4,406 658 -3,163 -624 -1,284 1,223
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3,660 2,348 -16,267 -754 457 -2,849 1,988 -1,855 529 -225 2,225
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.23 1.20 1.55 1.07 0.77 1.05 0.86 1.30 1.56 4.65 4.53
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.00 1.63 0.97 0.86 0.63 0.63 0.56 0.68 0.74 1.51 2.07
Price to Earnings (P/E)
37.54 523.92 0.00 0.00 0.00 0.00 21.19 0.00 0.00 0.00 25.39
Dividend Yield
2.21% 3.88% 4.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
2.66% 0.19% 0.00% 0.00% 0.00% 0.00% 4.72% 0.00% 0.00% 0.00% 3.94%
Enterprise Value to Invested Capital (EV/IC)
1.99 1.08 1.16 1.03 0.92 1.02 0.96 1.09 1.17 2.08 2.49
Enterprise Value to Revenue (EV/Rev)
3.33 3.46 2.65 2.40 2.17 2.12 1.93 1.97 1.83 2.41 2.84
Enterprise Value to EBITDA (EV/EBITDA)
17.89 32.25 0.00 0.00 80.36 0.00 15.43 0.00 54.69 0.00 22.05
Enterprise Value to EBIT (EV/EBIT)
27.85 91.89 0.00 0.00 0.00 0.00 46.62 0.00 0.00 0.00 40.12
Enterprise Value to NOPAT (EV/NOPAT)
26.75 95.59 0.00 0.00 0.00 0.00 26.32 0.00 95.45 0.00 19.83
Enterprise Value to Operating Cash Flow (EV/OCF)
11.82 19.46 25.98 17.96 49.10 29.07 38.45 18.45 21.15 31.92 29.75
Enterprise Value to Free Cash Flow (EV/FCFF)
66.80 0.00 7.27 7.64 14.03 12.65 8.34 8.23 11.00 7.47 25.44
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.33 1.02 1.73 1.83 1.79 2.34 2.05 2.47 2.44 3.11 2.12
Long-Term Debt to Equity
0.28 0.93 1.54 1.69 1.63 2.06 1.92 2.22 2.23 2.80 1.89
Financial Leverage
0.21 0.58 1.23 1.68 1.68 1.85 1.99 1.98 2.09 2.16 1.85
Leverage Ratio
1.89 2.27 3.05 3.80 3.83 4.14 4.41 4.62 5.23 5.98 5.87
Compound Leverage Factor
1.89 2.27 3.05 3.80 3.83 4.14 4.41 4.62 5.23 5.98 5.87
Debt to Total Capital
24.94% 50.57% 63.40% 64.67% 64.11% 70.09% 67.21% 71.16% 70.94% 75.66% 67.99%
Short-Term Debt to Total Capital
3.98% 4.63% 7.12% 4.96% 5.59% 8.62% 4.16% 7.07% 5.98% 7.58% 7.36%
Long-Term Debt to Total Capital
20.96% 45.94% 56.28% 59.72% 58.52% 61.47% 63.05% 64.08% 64.96% 68.08% 60.62%
Preferred Equity to Total Capital
8.25% 5.11% 7.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.40% 2.34% 2.71% 2.43% 2.60% 2.80% 2.82% 2.66% 2.22% 1.48% 0.02%
Common Equity to Total Capital
66.41% 41.98% 26.80% 32.89% 33.29% 27.11% 29.98% 26.18% 26.84% 22.86% 32.00%
Debt to EBITDA
2.72 15.25 -2.00 -38.35 58.88 -9.10 11.59 -11.44 37.49 -79.04 7.55
Net Debt to EBITDA
0.82 14.83 -1.94 -35.99 54.56 -8.33 10.50 -9.93 31.39 -64.37 5.96
Long-Term Debt to EBITDA
2.28 13.85 -1.77 -35.41 53.75 -7.98 10.87 -10.30 34.33 -71.12 6.74
Debt to NOPAT
4.06 45.20 -2.65 -25.23 -86.77 -10.37 19.77 -13.79 65.43 -83.84 6.79
Net Debt to NOPAT
1.22 43.95 -2.57 -23.68 -80.40 -9.50 17.91 -11.97 54.79 -68.28 5.35
Long-Term Debt to NOPAT
3.41 41.06 -2.36 -23.30 -79.21 -9.09 18.54 -12.42 59.92 -75.45 6.06
Altman Z-Score
2.47 0.82 -0.42 0.22 0.20 -0.10 0.25 -0.12 0.09 0.21 0.72
Noncontrolling Interest Sharing Ratio
6.55% 13.44% 19.15% 17.67% 7.06% 8.13% 8.97% 8.87% 8.46% 6.99% 2.57%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.41 0.93 0.86 0.96 0.98 0.99 1.14 1.05 1.02 0.98 1.04
Quick Ratio
0.95 0.46 0.45 0.53 0.56 0.51 0.61 0.57 0.54 0.50 0.54
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
980 -36,205 7,953 5,747 2,618 2,795 3,677 3,565 2,629 5,330 1,928
Operating Cash Flow to CapEx
717.88% 431.74% 254.58% 375.73% 142.48% 210.38% 141.99% 290.15% 260.08% 250.40% 329.14%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.39 0.30 0.27 0.28 0.29 0.31 0.32 0.33 0.36 0.40 0.43
Accounts Receivable Turnover
3.65 3.40 2.98 2.82 2.94 3.25 3.49 3.63 4.46 5.12 5.10
Inventory Turnover
1.99 2.30 2.28 2.07 2.04 2.02 2.02 2.08 2.09 2.41 2.69
Fixed Asset Turnover
3.01 3.00 2.78 2.51 2.54 2.62 2.59 2.55 2.76 3.20 3.99
Accounts Payable Turnover
3.26 5.03 5.32 5.09 5.24 5.14 4.81 4.45 3.65 3.53 3.52
Days Sales Outstanding (DSO)
99.91 107.26 122.35 129.35 124.26 112.37 104.71 100.57 81.82 71.34 71.57
Days Inventory Outstanding (DIO)
183.40 158.82 160.43 176.65 178.64 180.29 181.11 175.59 174.80 151.23 135.69
Days Payable Outstanding (DPO)
111.95 72.55 68.63 71.76 69.69 70.97 75.83 82.00 99.91 103.40 103.84
Cash Conversion Cycle (CCC)
171.36 193.52 214.15 234.24 233.20 221.69 209.99 194.16 156.71 119.17 103.42
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
32,924 69,921 49,729 42,836 39,908 34,613 32,102 26,999 24,673 19,131 19,677
Invested Capital Turnover
0.61 0.43 0.37 0.39 0.41 0.45 0.48 0.51 0.61 0.76 0.89
Increase / (Decrease) in Invested Capital
1,468 36,997 -20,192 -6,893 -2,928 -5,295 -2,511 -5,103 -2,326 -5,542 546
Enterprise Value (EV)
65,494 75,714 57,801 43,930 36,725 35,353 30,679 29,334 28,930 39,802 49,061
Market Capitalization
59,048 35,626 21,272 15,709 10,702 10,576 8,835 10,129 11,703 24,972 35,807
Book Value per Share
$27.68 $29.25 $12.23 $14.44 $12.79 $9.15 $9.32 $7.03 $6.70 $4.74 $6.89
Tangible Book Value per Share
($0.23) ($35.61) ($28.80) ($23.77) ($20.24) ($17.81) ($15.62) ($14.50) ($13.43) ($12.53) ($10.35)
Total Capital
39,870 70,793 51,220 44,710 41,970 36,980 34,287 29,810 27,959 23,503 24,720
Total Debt
9,943 35,800 32,475 28,916 26,907 25,919 23,043 21,212 19,833 17,783 16,806
Total Long-Term Debt
8,358 32,524 28,829 26,700 24,562 22,731 21,617 19,103 18,161 16,002 14,986
Net Debt
2,997 34,812 31,512 27,134 24,932 23,742 20,878 18,411 16,607 14,483 13,250
Capital Expenditures (CapEx)
772 901 874 651 525 578 562 548 526 498 501
Debt-free, Cash-free Net Working Capital (DFCFNWC)
32 1,028 144 -94 160 852 807 -110 -1,316 -1,763 -1,246
Debt-free Net Working Capital (DFNWC)
6,978 2,016 1,107 1,688 2,135 3,029 2,972 2,691 1,910 1,537 2,310
Net Working Capital (NWC)
5,393 -1,260 -2,539 -528 -210 -159 1,546 582 238 -244 490
Net Nonoperating Expense (NNE)
851 481 4,210 1,326 690 1,599 710 961 918 1,747 1,056
Net Nonoperating Obligations (NNO)
2,997 34,928 30,984 27,042 24,845 23,552 20,858 18,401 16,547 13,411 11,763
Total Depreciation and Amortization (D&A)
1,308 1,524 2,112 1,842 1,722 1,557 1,330 1,308 1,153 1,059 1,002
Debt-free, Cash-free Net Working Capital to Revenue
0.16% 4.69% 0.66% -0.51% 0.95% 5.11% 5.08% -0.74% -8.30% -10.66% -7.22%
Debt-free Net Working Capital to Revenue
35.51% 9.20% 5.07% 9.24% 12.64% 18.18% 18.72% 18.03% 12.05% 9.29% 13.39%
Net Working Capital to Revenue
27.44% -5.75% -11.62% -2.89% -1.24% -0.95% 9.74% 3.90% 1.50% -1.47% 2.84%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.84 $0.00 ($16.26) ($2.35) ($0.91) ($3.64) $0.38 ($2.12) ($0.50) ($1.45) $1.23
Adjusted Weighted Average Basic Shares Outstanding
855M 0.00 1.02B 1.02B 1.09B 1.10B 1.10B 1.11B 1.12B 1.13B 1.15B
Adjusted Diluted Earnings per Share
$1.82 $0.00 ($16.26) ($2.35) ($0.91) ($3.64) $0.38 ($2.12) ($0.50) ($1.45) $1.21
Adjusted Weighted Average Diluted Shares Outstanding
1.02B 0.00 1.12B 1.02B 1.09B 1.10B 1.11B 1.11B 1.12B 1.13B 1.16B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.02B 0.00 1.12B 1.09B 1.09B 1.10B 1.10B 1.11B 1.12B 1.13B 1.15B
Normalized Net Operating Profit after Tax (NOPAT)
3,768 3,760 3,633 2,212 1,958 2,168 2,173 1,958 2,271 2,364 2,753
Normalized NOPAT Margin
19.18% 17.17% 16.62% 12.11% 11.59% 13.01% 13.68% 13.12% 14.33% 14.29% 15.95%
Pre Tax Income Margin
11.97% 3.76% -84.10% -14.21% -7.49% -26.45% 4.14% -21.19% -3.94% -7.76% 7.09%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
72.32% 500.96% -7.29% -0.89% -5.20% 0.00% 0.00% 0.00% 0.00% -3.98% 23.98%
Augmented Payout Ratio
99.81% 500.96% -7.29% -0.89% -5.20% 0.00% 0.00% 0.00% 0.00% -3.98% 23.98%

Quarterly Metrics And Ratios for Teva Pharmaceutical Industries

This table displays calculated financial ratios and metrics derived from Teva Pharmaceutical Industries' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 1,164,426,972.00 1,165,296,084.00 1,166,826,784.00
DEI Adjusted Shares Outstanding
- - - - - - - - 1,164,426,972.00 1,165,296,084.00 1,166,826,784.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - 0.32 -0.49 0.20
Growth Metrics
- - - - - - - - - - -
Revenue Growth
4.32% 7.37% 12.52% -5.12% 1.89% 0.29% 3.42% 11.40% 2.34% -0.81% -1.90%
EBITDA Growth
-732.26% 102.09% -118.39% -97.15% 374.49% 3,384.62% 1,495.31% 1,450.00% 25.46% -147.24% -38.97%
EBIT Growth
-71.43% 73.32% -596.92% -148.81% 162.82% 182.52% 299.69% 132.79% 48.30% -324.14% -53.49%
NOPAT Growth
-1,576.92% 99.24% -108.74% -102.92% 354.50% 18,095.07% 1,752.16% 8,811.21% 42.14% -125.67% -5.58%
Net Income Growth
-65.61% 3.53% -606.49% -159.10% 152.51% 132.38% 211.28% 274.28% 67.73% -303.18% -46.08%
EPS Growth
40.00% 3.85% -750.00% -145.24% 250.00% 132.00% 194.87% 321.05% 72.22% -304.17% -45.95%
Operating Cash Flow Growth
14.48% -68.21% 13,760.00% -51.44% 15.32% 120.39% -46.75% 101.39% 61.90% 81.06% -34.69%
Free Cash Flow Firm Growth
-31.76% -34.78% -23.22% 82.76% 91.79% 43.28% -13.78% -77.86% -86.80% -70.77% -26.31%
Invested Capital Growth
-10.18% -9.46% -11.62% -22.46% -18.94% -12.24% -8.55% 2.85% -0.55% -5.77% -6.29%
Revenue Q/Q Growth
-14.31% 9.03% 4.03% -2.38% -7.99% 7.32% 7.28% 5.16% -15.47% 4.02% 6.11%
EBITDA Q/Q Growth
-126.52% 106.63% -592.31% 134.38% 2,345.45% -15.80% 97.13% -61.81% 97.95% -131.70% 354.67%
EBIT Q/Q Growth
-198.94% 47.44% -31.30% 23.53% 219.03% -30.95% 217.73% -87.44% 438.27% -204.36% 165.93%
NOPAT Q/Q Growth
-123.09% 97.71% -920.00% 43.14% 2,013.14% 62.17% -6.35% 199.82% -68.78% -129.29% 444.42%
Net Income Q/Q Growth
-196.77% -108.59% 55.38% 29.23% 179.71% 28.64% 53.36% 10.83% -23.28% -255.83% 140.70%
EPS Q/Q Growth
-131.58% -525.00% 48.00% 51.28% 194.74% 33.33% 54.17% 13.51% -26.19% -258.06% 140.82%
Operating Cash Flow Q/Q Growth
-110.47% 183.06% 572.82% -17.03% -118.26% 316.19% 62.56% 213.82% -103.45% 1,127.50% -41.36%
Free Cash Flow Firm Q/Q Growth
-12.92% -7.16% 19.25% 90.98% -9.30% -30.64% -28.24% -50.96% -45.92% 53.59% 80.92%
Invested Capital Q/Q Growth
-1.11% -4.73% -4.18% -14.06% 3.32% 3.15% -0.15% -3.35% -0.10% -2.27% -0.70%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
46.37% 48.61% 49.58% 50.15% 48.24% 50.34% 51.43% 56.36% 49.52% 51.98% 55.52%
EBITDA Margin
-5.13% 0.31% -1.48% 0.52% 13.83% 10.85% 19.93% 7.24% 16.95% -5.17% 12.40%
Operating Margin
-5.71% -0.12% -1.18% -0.69% 13.34% 10.90% 19.69% 6.39% 16.37% -5.58% 16.25%
EBIT Margin
-12.25% -5.91% -7.46% -5.84% 7.56% 4.86% 14.40% 1.72% 10.95% -10.99% 6.83%
Profit (Net Income) Margin
-10.97% -20.99% -9.00% -6.53% 5.65% 6.78% 9.69% 10.21% 9.27% -13.88% 5.32%
Tax Burden Percent
89.72% 355.28% 120.37% 111.74% 74.83% 139.41% 67.18% 601.25% 84.44% 126.37% 78.00%
Interest Burden Percent
99.79% 100.00% 100.31% 100.00% 100.00% 100.00% 100.16% 98.77% 100.23% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 25.17% -38.42% 33.13% -487.50% 15.33% 0.00% 22.00%
Return on Invested Capital (ROIC)
-2.48% -0.06% -0.58% -0.36% 7.51% 11.50% 10.36% 33.39% 12.20% -3.41% 11.07%
ROIC Less NNEP Spread (ROIC-NNEP)
-3.99% -5.08% -2.69% -2.07% 6.40% 9.20% 9.29% 23.16% 10.73% -6.72% 8.40%
Return on Net Nonoperating Assets (RNNOA)
-8.73% -12.34% -6.51% -4.48% 14.06% 20.76% 19.74% 42.76% 18.45% -11.52% 13.35%
Return on Equity (ROE)
-11.22% -12.39% -7.09% -4.84% 21.58% 32.26% 30.11% 76.14% 30.65% -14.93% 24.42%
Cash Return on Invested Capital (CROIC)
11.35% 12.44% 13.76% 24.34% 22.30% 15.91% 15.22% 9.94% 13.76% 13.91% 16.51%
Operating Return on Assets (OROA)
-4.55% -2.28% -2.98% -2.33% 3.09% 1.98% 5.92% 0.74% 4.84% -4.76% 2.94%
Return on Assets (ROA)
-4.07% -8.10% -3.60% -2.61% 2.31% 2.77% 3.98% 4.40% 4.10% -6.01% 2.30%
Return on Common Equity (ROCE)
-10.51% -11.64% -6.63% -4.50% 21.15% 31.75% 29.40% 74.18% 30.62% -14.92% 24.40%
Return on Equity Simple (ROE_SIMPLE)
-10.73% -11.78% -20.05% 0.00% -21.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-153 -3.50 -36 -20 388 630 590 1,768 552 -162 557
NOPAT Margin
-4.00% -0.08% -0.82% -0.48% 9.98% 15.08% 13.17% 37.54% 13.86% -3.90% 12.67%
Net Nonoperating Expense Percent (NNEP)
1.51% 5.03% 2.11% 1.71% 1.11% 2.30% 1.08% 10.23% 1.47% 3.31% 2.67%
Return On Investment Capital (ROIC_SIMPLE)
- - - -0.09% 1.69% 2.62% 2.45% 7.15% 2.22% -0.66% 2.25%
Cost of Revenue to Revenue
53.63% 51.39% 50.39% 49.89% 51.76% 49.66% 48.57% 43.64% 50.50% 48.02% 44.48%
SG&A Expenses to Revenue
7.28% 6.80% 6.88% 7.14% 7.63% 7.30% 7.08% 7.81% 7.63% 7.65% 6.78%
R&D to Revenue
6.34% 6.46% 5.54% 5.84% 6.35% 5.84% 5.71% 5.65% 5.58% 23.42% 6.76%
Operating Expenses to Revenue
52.06% 48.75% 50.74% 50.84% 34.85% 39.44% 31.74% 49.99% 33.12% 57.56% 39.27%
Earnings before Interest and Taxes (EBIT)
-468 -246 -323 -247 294 203 645 81 436 -455 300
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-196 13 -64 22 538 453 893 341 675 -214 545
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.17 2.89 3.37 4.65 2.78 2.82 3.20 4.53 4.21 5.09 5.78
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.99 1.13 1.22 1.51 1.05 1.16 1.38 2.07 2.00 2.28 2.68
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 32.55 25.39 22.13 55.80 91.02
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.07% 3.94% 4.52% 1.79% 1.10%
Enterprise Value to Invested Capital (EV/IC)
1.34 1.51 1.63 2.08 1.64 1.68 1.86 2.49 2.42 2.73 3.08
Enterprise Value to Revenue (EV/Rev)
2.05 2.15 2.17 2.41 1.95 2.06 2.25 2.84 2.74 3.03 3.41
Enterprise Value to EBITDA (EV/EBITDA)
108.39 37.35 69.32 0.00 63.63 36.14 19.81 22.05 20.12 30.91 43.64
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 42.19 40.12 34.81 74.10 162.39
Enterprise Value to NOPAT (EV/NOPAT)
205.11 57.00 108.09 0.00 106.61 54.80 28.19 19.83 18.25 33.23 29.76
Enterprise Value to Operating Cash Flow (EV/OCF)
23.57 29.96 19.61 31.92 25.58 24.67 35.43 29.75 27.73 27.60 33.21
Enterprise Value to Free Cash Flow (EV/FCFF)
11.20 11.50 11.15 7.47 6.58 9.88 11.65 25.44 17.52 19.03 18.06
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
2.60 2.84 2.97 3.11 2.66 2.52 2.31 2.12 2.02 2.14 2.09
Long-Term Debt to Equity
2.20 2.52 2.57 2.80 2.59 2.45 2.31 1.89 1.70 1.56 1.59
Financial Leverage
2.19 2.43 2.41 2.16 2.20 2.26 2.13 1.85 1.72 1.71 1.59
Leverage Ratio
5.34 5.92 6.03 5.98 5.88 6.08 5.98 5.87 5.41 5.48 5.24
Compound Leverage Factor
5.33 5.92 6.05 5.98 5.88 6.08 5.99 5.80 5.42 5.48 5.24
Debt to Total Capital
72.26% 73.96% 74.83% 75.66% 72.65% 71.60% 69.83% 67.99% 66.89% 68.14% 67.68%
Short-Term Debt to Total Capital
11.26% 8.31% 10.17% 7.58% 1.84% 1.93% 0.10% 7.36% 10.51% 18.48% 16.35%
Long-Term Debt to Total Capital
61.00% 65.65% 64.66% 68.08% 70.81% 69.67% 69.73% 60.62% 56.38% 49.66% 51.33%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.97% 0.81% 1.26% 1.48% 0.03% 0.03% 0.02% 0.02% 0.02% 0.02% 0.02%
Common Equity to Total Capital
26.77% 25.23% 23.91% 22.86% 27.32% 28.37% 30.15% 32.00% 33.10% 31.84% 32.30%
Debt to EBITDA
65.05 19.89 36.15 -79.04 32.71 18.15 8.81 7.55 7.04 9.79 12.41
Net Debt to EBITDA
55.14 17.48 29.83 -64.37 29.38 15.88 7.65 5.96 5.46 7.63 9.38
Long-Term Debt to EBITDA
54.91 17.66 31.24 -71.12 31.89 17.66 8.80 6.74 5.93 7.13 9.41
Debt to NOPAT
123.08 30.36 56.37 -83.84 54.81 27.53 12.53 6.79 6.39 10.52 8.46
Net Debt to NOPAT
104.34 26.69 46.51 -68.28 49.22 24.07 10.89 5.35 4.95 8.20 6.39
Long-Term Debt to NOPAT
103.91 26.95 48.71 -75.45 53.42 26.79 12.52 6.06 5.38 7.67 6.42
Altman Z-Score
0.12 0.16 0.18 0.30 0.25 0.29 0.44 0.63 0.66 0.59 0.81
Noncontrolling Interest Sharing Ratio
6.29% 6.04% 6.48% 6.99% 1.97% 1.58% 2.36% 2.57% 0.08% 0.08% 0.06%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.89 0.89 0.89 0.98 1.03 1.06 1.11 1.04 1.01 0.88 0.95
Quick Ratio
0.47 0.46 0.49 0.50 0.46 0.48 0.52 0.54 0.53 0.46 0.51
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
2,611 2,425 2,891 5,522 5,008 3,474 2,493 1,222 661 1,015 1,837
Operating Cash Flow to CapEx
-100.00% 106.19% 468.24% 445.74% -82.68% 236.46% 271.32% 815.49% -23.81% 391.43% 200.83%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.37 0.39 0.40 0.40 0.41 0.41 0.41 0.43 0.44 0.43 0.43
Accounts Receivable Turnover
4.64 4.46 4.90 5.12 4.86 4.54 4.61 5.10 5.12 4.91 4.51
Inventory Turnover
2.03 2.05 2.10 2.41 2.35 2.26 2.30 2.69 2.59 2.45 2.47
Fixed Asset Turnover
2.82 2.89 2.97 3.20 3.24 3.20 3.20 3.99 4.02 3.96 4.02
Accounts Payable Turnover
3.39 3.38 3.62 3.53 3.57 3.45 3.54 3.52 3.40 3.15 3.27
Days Sales Outstanding (DSO)
78.58 81.84 74.50 71.34 75.13 80.45 79.11 71.57 71.29 74.38 81.00
Days Inventory Outstanding (DIO)
180.22 178.26 173.80 151.23 155.47 161.66 158.70 135.69 140.94 148.94 147.99
Days Payable Outstanding (DPO)
107.68 108.12 100.92 103.40 102.17 105.92 103.00 103.84 107.21 115.70 111.76
Cash Conversion Cycle (CCC)
151.12 151.98 147.39 119.17 128.43 136.20 134.81 103.42 105.02 107.61 117.22
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
24,387 23,233 22,261 19,131 19,767 20,389 20,358 19,677 19,658 19,212 19,078
Invested Capital Turnover
0.62 0.67 0.71 0.76 0.75 0.76 0.79 0.89 0.88 0.87 0.87
Increase / (Decrease) in Invested Capital
-2,764 -2,428 -2,927 -5,542 -4,620 -2,844 -1,903 546 -109 -1,177 -1,280
Enterprise Value (EV)
32,735 34,992 36,395 39,802 32,388 34,296 37,763 49,061 47,522 52,392 58,784
Market Capitalization
15,817 18,405 20,415 24,972 17,427 19,223 23,172 35,807 34,632 39,451 46,146
Book Value per Share
$6.48 $5.61 $5.35 $4.74 $5.52 $5.95 $6.32 $6.89 $7.16 $6.66 $6.85
Tangible Book Value per Share
($13.17) ($13.23) ($13.08) ($12.53) ($11.82) ($11.57) ($11.01) ($10.35) ($9.74) ($9.90) ($9.50)
Total Capital
27,187 25,204 25,363 23,503 22,920 24,061 24,044 24,720 24,859 24,349 24,702
Total Debt
19,644 18,641 18,980 17,783 16,651 17,227 16,790 16,806 16,627 16,592 16,718
Total Long-Term Debt
16,584 16,547 16,400 16,002 16,230 16,763 16,766 14,986 14,015 12,092 12,680
Net Debt
16,653 16,383 15,661 14,483 14,954 15,066 14,587 13,250 12,886 12,937 12,633
Capital Expenditures (CapEx)
124 97 148 129 127 96 136 142 168 105 120
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1,426 -1,569 -2,222 -1,763 -905 -938 -934 -1,246 -951 -1,041 -870
Debt-free Net Working Capital (DFNWC)
1,565 689 1,097 1,537 792 1,223 1,269 2,310 2,790 2,614 3,215
Net Working Capital (NWC)
-1,495 -1,405 -1,483 -244 371 759 1,245 490 178 -1,886 -823
Net Nonoperating Expense (NNE)
266 871 354 256 168 347 156 1,287 183 413 323
Net Nonoperating Obligations (NNO)
16,844 16,670 15,878 13,411 13,498 13,555 13,104 11,763 11,426 11,455 11,094
Total Depreciation and Amortization (D&A)
272 259 259 269 244 250 248 260 239 241 245
Debt-free, Cash-free Net Working Capital to Revenue
-8.91% -9.63% -13.25% -10.66% -5.45% -5.64% -5.57% -7.22% -5.48% -6.01% -5.05%
Debt-free Net Working Capital to Revenue
9.78% 4.23% 6.54% 9.29% 4.77% 7.36% 7.56% 13.39% 16.08% 15.10% 18.66%
Net Working Capital to Revenue
-9.34% -8.62% -8.84% -1.47% 2.23% 4.56% 7.42% 2.84% 1.03% -10.89% -4.78%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.12) ($0.75) ($0.39) ($0.19) $0.19 $0.25 $0.38 $0.41 $0.32 ($0.49) $0.20
Adjusted Weighted Average Basic Shares Outstanding
1.12B 1.13B 1.13B 1.13B 1.14B 1.15B 1.15B 1.15B 1.16B 1.17B 1.17B
Adjusted Diluted Earnings per Share
($0.12) ($0.75) ($0.39) ($0.19) $0.18 $0.24 $0.37 $0.42 $0.31 ($0.49) $0.20
Adjusted Weighted Average Diluted Shares Outstanding
1.12B 1.13B 1.13B 1.13B 1.16B 1.16B 1.16B 1.16B 1.18B 1.17B 1.18B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.13B 1.13B 1.13B 1.13B 1.15B 1.15B 1.15B 1.15B 1.16B 1.17B 1.17B
Normalized Net Operating Profit after Tax (NOPAT)
449 573 703 639 527 627 714 886 642 118 939
Normalized NOPAT Margin
11.75% 13.77% 16.22% 15.11% 13.54% 15.00% 15.94% 18.81% 16.12% 2.84% 21.37%
Pre Tax Income Margin
-12.23% -5.91% -7.48% -5.84% 7.56% 4.86% 14.42% 1.70% 10.97% -10.99% 6.83%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% -3.98% -25.76% -208.59% 51.44% 23.98% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -3.98% -25.76% -208.59% 51.44% 23.98% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Teva’s Q2 2026 results show improving underlying margins and a stronger balance sheet, but quarterly earnings remain highly volatile. Revenue was $4.14 billion, up slightly from $4.18 billion in Q2 2025 but below the $4.71 billion reported in Q4 2025. Compared with Q2 2023, revenue has increased approximately 7%, indicating moderate top-line growth over the period.

Gross profit reached $2.15 billion in Q2 2026, producing a gross margin of roughly 52%. That compares with approximately 50% in Q2 2025, 49% in Q2 2024 and 46% in Q2 2023. The expanding gross margin is an encouraging sign that product mix, pricing or manufacturing efficiency may be improving.

However, Teva reported a $231 million operating loss and a $575 million consolidated net loss in Q2 2026, or a diluted loss of $0.49 per share. This compares with a $369 million profit in Q1 2026 and a $481 million profit in Q4 2025. The latest loss was affected by $147 million of restructuring charges, $230 million of other special charges and a $22 million impairment charge. These items highlight the risk that restructuring and other nonrecurring costs will continue to obscure the company’s underlying profitability.

Cash generation improved sequentially. Total operating cash flow was $411 million in Q2 2026, compared with negative $40 million in Q1 2026 and $227 million in Q2 2025. Teva also reported a $714 million increase in cash during the quarter, although investing activities used $492 million. Cash and equivalents ended Q2 at $3.66 billion, down modestly from $3.74 billion in Q1 but substantially above $2.16 billion in Q2 2025.

The balance sheet has strengthened over the longer term. Total debt declined to approximately $16.6 billion in Q2 2026 from $17.2 billion in Q2 2025, $18.6 billion in Q2 2024 and $21.5 billion in Q2 2023. Total liabilities also fell to $32.1 billion from $33.3 billion a year earlier and $35.4 billion in Q2 2024. Equity increased to $7.76 billion, although it remains constrained by accumulated retained losses.

  • Gross-margin expansion: Q2 2026 gross margin was approximately 52%, up from about 46% in Q2 2023, suggesting improving profitability at the product level.
  • Debt reduction: Total short- and long-term debt declined to roughly $16.6 billion, down from approximately $21.5 billion in Q2 2023.
  • Improved cash position: Cash and equivalents of $3.66 billion were about $1.49 billion higher than in Q2 2025, providing greater financial flexibility.
  • Better operating cash flow: Q2 operating cash flow improved to $411 million from negative $40 million in Q1 2026 and $227 million in the year-ago quarter.
  • Lower overall liabilities: Total liabilities fell to $32.1 billion in Q2 2026 from $35.4 billion in Q2 2024, while total equity rose from $6.56 billion to $7.76 billion over the same period.
  • Revenue has broadly stabilized: Quarterly revenue has remained near $4 billion to $4.7 billion, but Q2 2026 revenue was slightly below Q2 2025 and well below Q4 2025.
  • Cash flow remains uneven: Operating cash flow was positive in Q2 2026 but negative in Q1 2026, reflecting continuing working-capital volatility.
  • Return to a large quarterly loss: The $575 million Q2 net loss reversed the $369 million profit recorded in Q1 2026 and resulted in a $0.49 diluted loss per share.
  • High special charges: Restructuring and other special charges totaled $377 million in Q2 2026, making it difficult to assess recurring operating earnings.
  • Liquidity remains tight: Q2 current liabilities of $15.65 billion exceeded current assets of $13.76 billion, producing a current ratio below 1.0 despite the company’s sizeable cash balance.

For investors, the key question is whether Teva can convert its improving gross margin and debt reduction into consistent net profitability. The financial statements show meaningful progress in cash generation and leverage, but the Q2 loss, elevated special charges, negative retained earnings and sub-1.0 current ratio remain important risks.

11/16/26 12:16 PM ETAI Generated. May Contain Errors.

Teva Pharmaceutical Industries Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Teva Pharmaceutical Industries' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Teva Pharmaceutical Industries' net income appears to be on an upward trend, with a most recent value of $1.42 billion in 2025, falling from $1.60 billion in 2015. The previous period was -$1.96 billion in 2024. See where experts think Teva Pharmaceutical Industries is headed by visiting Teva Pharmaceutical Industries' forecast page.

Teva Pharmaceutical Industries' total operating income in 2025 was $2.16 billion, based on the following breakdown:
  • Total Gross Profit: $8.94 billion
  • Total Operating Expenses: $6.78 billion

Over the last 10 years, Teva Pharmaceutical Industries' total revenue changed from $19.65 billion in 2015 to $17.26 billion in 2025, a change of -12.2%.

In the past 13 quarters, Teva Pharmaceutical Industries' cash and equivalents has ranged from $1.70 billion in Q1 2025 to $4.09 billion in Q3 2026, and is currently $4.09 billion as of their latest financial filing in Q3 2026.

Teva Pharmaceutical Industries had total debt of $16.81 billion at the end of 2025, a 5.5% decrease from 2024, and a 69.0% increase since 2015.

Over the last 10 years, Teva Pharmaceutical Industries' book value per share changed from 27.68 in 2015 to 6.89 in 2025, a change of -75.1%.



Financial statements for NYSE:TEVA last updated on 11/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners